| Abstrakt: |
Using X-ray fluorescence spectrometry, platinum concentrations were determined in autopsy tissue samples from 12 patients who had received cis-diamminedichloroplatinum (DDP) 20-120 mg/m up to 6 months antemortem. Tissue platinum concentrations were highest in liver (0.5-3.7 μg/g wet weight), prostate (1.6-3.6 μg/g), and kidney (0.4-2.9 μg/g), somewhat lower in bladder, muscle, testicle, pancreas, and spleen, and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum, Platinum concentrations in tumors were generally somewhat lower than the concentration in the organ in which the tumor was located, with the exception of intracerebral tumors. Different metastatic sites in the same patient had substantially different platinum concentrations and hepatic metasutases had the highest concentrations. Intra-arterial administration of drug may augment tissue concentrations of platinum. In a patient undergoing therapeutic abortion 4 days after treatment, the platinum concentration was 0.5 μg/g in the placenta and 0.3 μg/g in the fetus. The data suggest that for in vitro sensitivity testing, DDP concentrations of ≦7 μg/ml should be used. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink